Maxim Group initiated coverage on CohBar with a new price target
$CWBR
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Maxim Group initiated coverage of CohBar with a rating of Buy and set a new price target of $3.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2021 | $5.00 | Speculative Buy → Buy | WBB Securities |
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a "public shell," and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing requirements under Nasdaq Listing Rule 5605 and certain of Nasdaq's filing requirements under Nasdaq Listing Rule 5250(c)(1)
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. ("Morphogenesis"), for an all-stock transaction to advance a late-stage oncology pipeline. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market ("Nasdaq"). The transaction is exp
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fa. and MENLO PARK, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology compa
25-NSE - CohBar, Inc. (0001522602) (Subject)
8-K - CohBar, Inc. (0001522602) (Filer)
8-K - CohBar, Inc. (0001522602) (Filer)
WBB Securities upgraded CohBar from Speculative Buy to Buy and set a new price target of $5.00
Maxim Group initiated coverage of CohBar with a rating of Buy and set a new price target of $3.00
Aegis Capital initiated coverage of CohBar with a rating of Buy and set a new price target of $6.00
4 - CohBar, Inc. (0001522602) (Issuer)
4 - CohBar, Inc. (0001522602) (Issuer)
4 - CohBar, Inc. (0001522602) (Issuer)